Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S, Watanabe LRM, Oliveira EA, Faião-Flores F, Migliorini S, Tiago M, Felipe-Silva A, Vazquez VL, da Costa Souza P, Consolaro MEL, Campa A, Maria-Engler SS.
Sandri S, et al.
Pharmacol Res. 2020 Sep;159:104998. doi: 10.1016/j.phrs.2020.104998. Epub 2020 Jun 11.
Pharmacol Res. 2020.
PMID: 32535222
Free article.